June 1, 2026 · Form 4 insider transaction
Lin Shao-Lee bought 45,453 shares of Cue Biopharma, Inc., a transaction worth N/A. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 2 days after the transaction.
On April 30, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold pre-funded warrants and accompanying warrants to purchase shares of common stock in a private placement that closed on May 4, 2026. The purchase price for each pre-funded warrant and accompanying warrants to purchase one-half of one share of common stock was $11.00. The pre-funded warrants and accompanying warrants became exercisable on June 1, 2026, following approval by the Issuer's stockholders of the issuance of common stock upon exercise of the pre-funded warrants and accompanying warrants in accordance with applicable listing rules of the Nasdaq Stock Market, including Nasdaq Listing Rule 5636, at the Issuer's Special Meeting of Stockholders held on June 1, 2026.; The securities are held by the Shao-Lee Lin Trust, DTD 3/13/2023.